Kidney disease: New drug shows tremendous promise; offers hope beyond diabetes

For millions of people who are suffering from chronic kidney disease (CKD), diagnosis comes with a tough truth: you can feel fine for years while your kidneys quietly fail and your risk for heart disease, hospital stays, and early death just keeps climbing.

Treatments have improved, but for many, especially those without diabetes, there haven’t been many good options.That’s finally starting to change.A wave of new studies has given CKD patients worldwide a genuine reason to hope. Researchers have found that finerenone, which is a drug already used for kidney disease tied to type 2 diabetes, doesn’t just help those with diabetes. The benefits reach far more people than anyone thought.

We're talking about slower kidney decline, lower risk of kidney failure, fewer heart issues, and, yes, longer lives for people battling CKD without diabetes.Since nearly 800 million people worldwide have CKD, this isn’t a minor story. It could shake up public health everywhere.

Chronic Kidney Disease: A silent epidemic

CKD is one of the world’s fastest-growing medical problems. When your kidneys lose their ability to filter waste, you’re suddenly at risk for everything from heart attacks to dialysis.

Traditionally, doctors focus on controlling blood pressure and diabetes, and on managing protein in the urine. It helps, but even the best available care often can’t stop the slide towards failure. The search has been on for treatments that do more than manage symptoms — they needed something that goes after CKD at its root.

Finerenone: What does the drug do?

Finerenone is a non-steroidal medicine that blocks the overactive mineralocorticoid receptor, which is a key player in inflammation and scarring in the kidneys and heart. Doctors already used it for diabetic kidney disease, but the big question was: could it work for everyone else?The answer’s coming in loud and clear.

The new studies say yes.

FIND-CKD: Making waves in kidney research

The highlight is the FIND-CKD trial, a massive study with more than 1,500 patients across 24 countries, led by clinical pharmacologist Hiddo Lambers Heerspink of the University Medical Center Groningen. Finerenone, added to regular care, noticeably slowed kidney decline compared to standard treatment alone. Even better, the drug slashed the chance of kidney failure, disease progression, heart failure, or dying from heart trouble by a solid 23%.Heerspink said, “In the finerenone group, 13.9 percent experienced such a complication, compared to 16.9 percent in the placebo group. That amounts to a reduction in risk of approximately 23 percent.”Numbers like that matter because they mean more people stay off dialysis and can avoid a transplant. The results were published in the New England Journal of Medicine and drew attention at the 2026 European Renal Association Congress.

Is there hope for the toughest kidney diseases?

One arm of the research zoomed in on glomerular diseases, which are rare disorders that mess up the kidneys’ filtering units, often hitting younger people. Finerenone dropped the risk of failure or worsening disease by 26% and cut the level of protein in the urine by 42% in just a year. These are major wins for a group used to slim odds.Per Heerspink, “The presence of protein in the urine is often an important and early sign of kidney damage.

In the finerenone group, it decreased by an average of over 41 percent, compared to about 9 percent in the placebo group. More than half of the patients who received finerenone achieved a reduction of at least 30 percent in the amount of protein in their urine. Such a reduction is an important indicator of a more favorable renal prognosis.

”

INFINITY study: Benefits for all CKD patients

But the real jaw-dropper came from the INFINITY study. Researchers pooled data from three major trials, totaling over 14,000 patients — both diabetic and non-diabetic.

The verdict: across all CKD types, finerenone reduced kidney failure/progression by 24%, cut hospitalization and death from heart problems by 20%, and even lowered the risk of death from any cause by 12%. Didn’t matter what caused the kidney trouble; most patients benefited.Heerspink said, “Now it turns out the drug is also effective in people without diabetes, even though more than half of all CKD patients worldwide are non-diabetic.

Chronic kidney disease now affects an estimated 800 million adults worldwide.”

Why is everyone talking about Finerenone?

CKD isn’t just a “diabetes thing”; most people with CKD actually don’t have diabetes. Until now, those folks had hardly any proven treatments. If more countries approve finerenone for all CKD types, millions could benefit. This research also signals a shift in medicine, focusing less on what originally caused CKD and more on the common processes that keep it getting worse.Per Heerspink, “Finerenone could become an important new treatment option for people with chronic kidney disease who do not have diabetes. The drug offers a clear delay in the decline of kidney function on top of current standard care. The results provide physicians with new therapeutic options to help preserve kidney function and reduce the number of cardiovascular and renal complications. And this applies to a broad, underserved patient population with non-diabetic CKD, for whom there are few treatment options in the guidelines.

”

What about the side effects?

No drug is perfect. With finerenone, some patients saw higher potassium levels (hyperkalemia), so doctors will need to monitor closely, especially for those already at risk. Overall, the drug was well tolerated, about what one would expect from its safety record so far.

Why it matters

It’s important to note that Finerenone isn’t a cure for CKD. But with CKD affecting nearly 800 million people and causing millions of deaths, even small advances have huge ripple effects. Here, the progress might be bigger than anyone expected. For patients living with the shadow of kidney failure, this isn’t just another headline — it’s real hope. And medicine doesn’t come hand that out every day.